Follow-up to: do statins cause or increase risk of diabetes
Question explored with the scientific record
How do statins compare with lifestyle or other cholesterol drugs?
The short version: statins increase diabetes risk modestly, lifestyle interventions cut it by about half, and the two are not equivalent trades.
The evidence for statin-induced diabetes is consistent across designs. A 2013 UK cohort of 285,864 people found a 14% relative increase in new-onset diabetes after statin initiation [5]. The JUPITER trial showed a 26% increase with rosuvastatin over two years [4, 7]. The 2025 Naples study of 13,674 people found the strongest diabetes risk at very low LDL levels (below 84 mg/dL), with an incidence of 27.6 per 1,000 person-years versus 8.4 at very high LDL [2]. That inverse relationship suggests the diabetes risk is partly independent of the drug and tied to low LDL itself.
Lifestyle interventions produce much larger risk reductions. The Finnish DPS trial cut diabetes incidence by 58% over 3.2 years [18]. The Indian IDPP-1 trial found lifestyle modification reduced cumulative incidence from 55% to 39% over 30 months [21]. The Spanish PreDE trial in primary care found a 32% relative risk reduction [17, 25]. These are not small effects. They match or exceed the cardiovascular benefit of statins in primary prevention.
| Intervention | Diabetes risk change | Population | Source |
|---|---|---|---|
| Statin initiation | +14% relative increase | 285,864 UK adults | [5] |
| Rosuvastatin vs placebo | +26% relative increase | 11,918 JUPITER trial | [4] |
| Lifestyle intervention | -58% relative reduction | 522 Finnish IGT adults | [18] |
| Lifestyle intervention | -32% relative reduction | 1,088 Spanish primary care | [17] |
| Metformin | -31% relative reduction | 531 Indian IGT adults | [21] |
The comparison with other lipid drugs is thin. The SEAS trial found simvastatin plus ezetimibe increased cancer incidence (11.1% vs 7.5%) but did not report diabetes separately [26]. No retrieved evidence directly compares diabetes risk across non-statin lipid drugs.
My call: for primary prevention, lifestyle intervention is clearly superior to statins on diabetes risk. The evidence for statins shows a real but modest harm. Confidence: high for the statin-diabetes link, high for lifestyle benefit, low for comparisons with other lipid drugs because the data does not exist.
Sources examined 26
-
Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study
Incident diabetes during statin therapy does not worsen cardiovascular outcomes and does not diminish the cardioprotective benefits of statins, based on two nationwide propensity-matched Korean cohorts.
DOI: 10.1186/s12933-025-03003-0 -
A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes
A six-year population-based cohort study in Naples, Italy shows an inverse association between LDL-cholesterol levels and incident type 2 diabetes risk that is largely independent of statin use, with the strongest risk at very low LDL-C and a statin-associated increase in risk o…
DOI: 10.1186/s12933-025-02964-6 -
Assessment of angiotensin receptor blockers for the hypertensive patients with high salt intake estimated with spot urine
This study investigates the relationship between cardiorespiratory fitness and the risk of developing type 2 diabetes mellitus in hypertensive patients undergoing statin therapy, finding that higher fitness levels are associated with a reduced risk of diabetes.
DOI: 10.1016/j.jash.2016.03.076 -
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus
This study investigates the association of lipoprotein subclasses and a novel lipoprotein insulin resistance (LPIR) score with the incidence of type 2 diabetes mellitus (T2DM) among individuals randomized to receive either rosuvastatin or placebo in the JUPITER trial, revealing …
DOI: 10.1001/jamacardio.2016.0096 -
Statins and Risk of Diabetes
Statin initiation in a large UK electronic medical record cohort is associated with a modest 14% increase in incident type 2 diabetes, not explained by differential survival, with the excess risk stronger for lipophilic statins like simvastatin and atorvastatin.
DOI: 10.2337/dc12-1756 -
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
A comprehensive review and practical guidance for clinicians on the diabetes risk associated with statin therapy, evaluating the evidence that statins modestly increase type 2 diabetes risk—especially at high doses—and outlining risk stratification, monitoring, and lifestyle mea…
DOI: 10.1016/j.atherosclerosissup.2014.04.001 -
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
This 2013 comprehensive review synthesizes evidence from randomized trials and meta-analyses to evaluate whether statin therapy increases the risk of new-onset diabetes, its magnitude, potential mechanisms, and clinical implications, concluding a small increased risk that is gen…
DOI: 10.1111/dom.12254 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin
This study investigates the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) in patients treated with atorvastatin across three large randomized clinical trials, revealing that high-dose atorvastatin is associated with a slight increase in diabetes …
DOI: 10.1016/j.jacc.2010.10.047 -
The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data
A large population-based Korean cohort study using NHIS data found that aspirin and statin use are linked to reduced lung cancer mortality (dose-dependent for higher exposure), metformin use is associated with reduced lung cancer incidence in diabetics (and mortality to a degree…
DOI: 10.1016/j.jtho.2020.08.021 -
Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria
In a 200-person prospective cohort of individuals with type 2 diabetes and microalbuminuria, toe-brachial index (TBI) and, to a lesser extent, ankle-brachial index (ABI) predicted incident cardiovascular disease and all-cause mortality over about 6 years, with TBI providing addi…
DOI: 10.1007/s00125-017-4344-x -
Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study
In individuals with type 2 diabetes from the ADVANCE trial, baseline LDL cholesterol was associated with incident dementia/cognitive decline, while statin use did not meaningfully alter dementia/CD risk over ~5 years.
DOI: 10.1186/s12933-025-02894-3 -
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
A post hoc analysis of the West of Scotland Coronary Prevention Study evaluating a modified NCEP metabolic syndrome definition using BMI and CRP; it shows metabolic syndrome predicts CHD and especially new-onset diabetes, CRP adds prognostic value, and pravastatin reduces CHD ri…
DOI: 10.1161/01.CIR.0000080897.52664.94 -
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
This study demonstrates that an intensive lifestyle intervention significantly reduces the incidence of type 2 diabetes in Japanese males with impaired glucose tolerance by promoting weight loss and healthy lifestyle changes.
DOI: 10.1016/j.diabres.2004.06.010 -
Lifestyle Intervention in Prevention of Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus: One-Year Results of the FIN-D2D Project
A large Finnish real-world study (FIN-D2D) compared the 1-year cardio-metabolic effects and type 2 diabetes incidence of a lifestyle intervention in high-risk women aged ≤45 with and without a history of gestational diabetes mellitus (GDM), finding overall benefit with no major …
DOI: 10.1089/jwh.2013.4520 -
Value of Lifestyle Intervention to Prevent Diabetes and Sequelae
This study demonstrates that lifestyle interventions can significantly reduce the incidence of type 2 diabetes and associated healthcare costs among individuals with prediabetes, particularly those meeting specific screening criteria.
DOI: 10.1016/j.amepre.2014.10.003 -
Effective translation of a type-2 diabetes primary prevention programme into routine primary care: The PreDE cluster randomised clinical trial
The PreDE cluster randomized clinical trial demonstrated that a lifestyle intervention program significantly reduced the incidence of type 2 diabetes among high-risk patients in routine primary care settings in the Basque Country.
DOI: 10.1016/j.diabres.2018.01.006 -
Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
This study demonstrates that lifestyle changes can significantly reduce the incidence of type 2 diabetes in high-risk individuals with impaired glucose tolerance.
DOI: 10.1056/NEJM200105033441801 -
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program (DPP) study demonstrated that troglitazone significantly reduced the incidence of type 2 diabetes in high-risk individuals during its limited use, but this effect did not persist after the drug was discontinued.
DOI: 10.2337/diabetes.54.4.1150 -
Lifestyle interventions for diabetes mellitus type 2 prevention
In a real-world Catalonia primary-care setting, this study evaluated the costs and effectiveness of intensive lifestyle interventions versus standard care to prevent type 2 diabetes in high-risk adults over about four years, finding substantial reductions in diabetes incidence a…
DOI: 10.1016/j.rceng.2013.11.003 -
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
This study investigates the effectiveness of lifestyle modification and metformin in preventing the progression of impaired glucose tolerance to type 2 diabetes in native Asian Indians, finding significant reductions in diabetes incidence with both interventions.
DOI: 10.1007/s00125-005-0097-z -
Evaluating a digital intervention for prevention of type 2 diabetes: protocol for a cluster-randomised controlled trial in urban and rural India
This protocol outlines a cluster-randomised controlled trial in urban and rural India to evaluate a digital intervention (My Sugar Journey) for preventing type 2 diabetes in adults with prediabetes, with the primary outcome being incidence of diabetes at 24 months and multiple s…
DOI: 10.1186/s12889-025-24337-0 -
Prediabetes and Lifestyle Modification: Time to Prevent a Preventable Disease
This study highlights the prevalence of prediabetes in the U.S. and emphasizes the importance of lifestyle modifications in preventing the progression to Type 2 diabetes, suggesting that such interventions can significantly reduce diabetes incidence and healthcare costs.
DOI: 10.7812/TPP/14-002 -
Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention
This study demonstrates the feasibility and effectiveness of an intensive lifestyle intervention in delaying the progression to type 2 diabetes among high-risk Spanish individuals in real-life primary healthcare settings.
DOI: 10.1007/s00125-012-2492-6 -
Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies
This study systematically reviews EU-wide interventional research on primary prevention of type 2 diabetes (T2D) in non-diabetic adults, finding that multicomponent lifestyle interventions (diet + physical activity + personalized counseling, especially Mediterranean-style diets …
DOI: 10.3390/nu17061053 -
At Sea with SEAS: The First Clinical Endpoint Trial for Ezetimibe, Treatment of Patients with Mild to Moderate Aortic Stenosis, Ends with Mixed Results and More Controversy
The SEAS trial investigated the effects of simvastatin and ezetimibe on cardiovascular events and aortic valve replacement in patients with mild to moderate aortic stenosis, finding a significant reduction in cardiovascular events but no impact on aortic valve progression or sur…
DOI: 10.1016/j.hlc.2009.02.007